Education
About Us
Working with TipRanks
Follow Us
Turn Therapeutics Inc (TTRX)
NASDAQ:TTRX
TTRX Stock Chart & Stats
$2.74
--
Market closed
$2.74
--
Day’s Range― - ―
52-Week Range$2.57 - $26.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.86M
Market Cap
$106.00M
Enterprise Value-$751.56K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.59
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,445,183
10 Day Avg. Volume2,856,380
30 Day Avg. Volume2,856,380
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.77Price Target Upside146.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical-stage Progression (GX-03 Phase 2)On-schedule Phase 2 progress and planned interim/topline readouts provide a clear technical de-risking pathway for the lead dermatology asset. Successful data would materially advance clinical validation, partnerability, and future revenue potential, making development-readiness a durable fundamental asset.
Strategic Medline Partnership And Commercial ChannelA multi-year supply and license agreement with a major distributor meaningfully strengthens commercial execution capability and market access. Partnering to scale manufacturing and distribution reduces execution risk and supports durable market expansion and earlier revenue pathways once approvals or sales begin.
Board Upgrade With Experienced Healthcare ExecutiveAdding a seasoned life-sciences and M&A executive improves governance and strategic capital allocation credibility. Strong board expertise enhances merger, partnership and financing execution over time, increasing the odds of disciplined deal-making and value-accretive strategic choices.
Bears Say
No Reported RevenueAbsent any product revenue, the business remains fully dependent on external financing or partnerships. This structural lack of top-line cash generation means long-term value hinges entirely on clinical and partnership success, increasing execution risk and time-to-commercialization dependency.
Ongoing Cash Burn And Negative Free Cash FlowSustained operating cash outflows without revenue create recurring financing needs and potential dilution. Continued burn pressures R&D cadence and commercialization pacing; management must secure durable funding or revenue to avoid disruption of clinical programs and strategic initiatives.
Negative Shareholders' EquityNegative equity signals accumulated losses and weak capitalization, constraining borrowing capacity and heightening reliance on dilutive financing. Over the medium term this increases governance scrutiny and reduces optionality for capital-intensive activities like late‑stage trials or manufacturing scale-up.
Turn Therapeutics Inc News
TTRX FAQ
What was Turn Therapeutics Inc’s price range in the past 12 months?
Turn Therapeutics Inc lowest stock price was $2.57 and its highest was $26.50 in the past 12 months.
What is Turn Therapeutics Inc’s market cap?
Turn Therapeutics Inc’s market cap is $106.00M.
When is Turn Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Turn Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Turn Therapeutics Inc overvalued?
According to Wall Street analysts Turn Therapeutics Inc’s price is currently Undervalued.
Does Turn Therapeutics Inc pay dividends?
Turn Therapeutics Inc does not currently pay dividends.
What is Turn Therapeutics Inc’s EPS estimate?
Turn Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Turn Therapeutics Inc have?
Turn Therapeutics Inc has 29,445,183 shares outstanding.
What happened to Turn Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Turn Therapeutics Inc?
Currently, no hedge funds are holding shares in TTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Turn Therapeutics Inc Stock Smart Score
Company Description
Turn Therapeutics Inc
Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.
TTRX Stock 12 Month Forecast
Average Price Target
$6.77
▲(146.96% Upside)
Technical Analysis
AIM ImmunoTech
―
Scinai Immunotherapeutics
―
Pulmatrix
―
Dermata Therapeutics
―
Azitra Inc
―
Ownership Overview
5.34% Insiders
0.12% Mutual Funds
0.60% Other Institutional Investors
93.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---